Piper Sandler raised the firm’s price target on Fulcrum Therapeutics (FULC) to $16 from $12.50 and keeps an Overweight rating on the shares. The firm notes Fulcrum will report 20mg pociredir data at ASH in December. Fulcrum disclosed that baseline HbF in the 12 patients enrolled was 7.1% mean. Piper is confident that 20mg pociredir will outperform the 12mg cohort across performance measures.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC: